PINL:GRPOF - Post by User
Comment by
FormerSupporteron Dec 10, 2020 1:39pm
119 Views
Post# 32077903
RE:Science
RE:Science Thanks for your comment. I believe that ARDS is not the problem. It make a nice addition to the pipeline. The problem is the lack of focus and funds to make ARDS or any of thier early stage assets a success. They keep on jumping from prospect to prospect righ before they take it into the clinic.
As mentioned I believe that ARDS, QIXLEEF and CAUMZS all have good potential but they are in the wrong hands. Tetra appears to be a discovery company. Find an early stage asset but no ability to develope it. This is almost completely due to the inability to raise sufficient money. The feeling with the old board was better not to dilute and never develope then take the risk. I hope the new directors are willing to get this company funded so that they can actually run a trial.
Given the history, I'm not excited for the future.